Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 6/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.41 |
| ▸ | CFTR | P13569 | 2/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.37 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.37 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25033934 | 0.86 | CRBN (0.53) | CRBNDDB1PDE3BPDE3AMCL1 | |
| SCHEMBL30135753 | 0.85 | CRBN (0.48) | CRBNDDB1PDE3BPDE3AMCL1 | |
| SCHEMBL30135802 | 0.85 | PDE3B (0.41) | CRBNDDB1PDE3BPDE3ACFTR | |
| SCHEMBL25035187 | 0.85 | PDE3B (0.41) | CRBNDDB1PDE3BPDE3ACFTR | |
| SCHEMBL25824324 | 0.84 | ALDH1A1 (0.42) | CRBNDDB1PDE3BPDE3ANPC1 | |
| SCHEMBL25033928 | 0.83 | PDE3B (0.41) | CRBNDDB1PDE3BPDE3ACFTR | |
| SCHEMBL25819151 | 0.72 | DDB1 (0.45) | CRBNDDB1 | |
| SCHEMBL25825109 | 0.72 | CRBN (0.42) | CRBNDDB1CFTRSUV39H2 | |
| SCHEMBL25821512 | 0.72 | CRBN (0.46) | CRBNDDB1MCL1KDM4D | |
| SCHEMBL30135745 | 0.72 | DDB1 (0.44) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | UPPTHERA, INC. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | CRBN 2136/4885DDB1 132/4885PDE3B 4485/4885 |
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | PLK1, BUB1B, BUB1 | CRBN 2496/4885DDB1 77/4885PDE3B 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.